Chugai Pharmaceutical Co., Ltd. v. Alexion Pharmaceuticals, Inc.
1:19-cv-02120
Overview
Parties
Defendant
Alexion Pharmaceuticals, Inc. Operating Company
Represented By
1 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Plaintiff
Chugai Pharmaceutical Co., Ltd. Operating Company
Represented By
3 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
JPMorgan Chase & Co.
JPMorgan Chase & Co., 4041 Ogletown Stanton Road
Shaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 7 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| π―π΅ Japan | Japan Counterpart | View Official Patent → | |
| π―π΅ Japan | Japan Counterpart | View Official Patent → | |
| π―π΅ Japan | Japan Counterpart | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US10472623
Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
|
Filed: 2018-04-13
Issued: 2019-11-12
|
Active (11.4 yrs remaining)
Expires: 2038-04-13
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).